EGFR mutation exists in squamous cell lung carcinoma.

Autor: Cheung AH; Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Hong Kong., Tong JH; Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Hong Kong., Chung LY; Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Hong Kong., Chau SL; Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Hong Kong., Ng CS; Division of Cardiothoracic Surgery, Department of Surgery, Prince of Wales Hospital, Hong Kong., Wan IYP; Division of Cardiothoracic Surgery, Department of Surgery, Prince of Wales Hospital, Hong Kong., To KF; Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, Hong Kong. Electronic address: kfto@cuhk.edu.hk.
Jazyk: angličtina
Zdroj: Pathology [Pathology] 2020 Apr; Vol. 52 (3), pp. 323-328. Date of Electronic Publication: 2020 Feb 27.
DOI: 10.1016/j.pathol.2019.12.003
Abstrakt: Whether EGFR mutation occurs in lung squamous cell carcinoma (SCC) remains a controversial issue. Although numerous trials have shown positive response to tyrosine kinase inhibitors in SCC, these observations have not been well correlated with presence or absence of EGFR mutation. A complicating issue is that adenosquamous carcinoma, a mimic of SCC, frequently harbours EGFR mutations. We evaluated the EGFR mutation status of 191 cases initially diagnosed as SCC of lung origin in years 2000-2011, and performed a panel of markers including p40, p63, CK5/6, TTF-1, mucicarmine on the tissue microarray or tissue blocks from each case, to ascertain the squamous differentiation of each case. Four cases were found to have EGFR mutations, with three showing typical squamous morphological features and immunohistochemical profile on all available tumour blocks, and one reclassified as adenosquamous carcinoma. Mixed responses were noted for two of the patients with EGFR-mutated SCC treated with tyrosine kinase inhibitors. In conclusion, we report that a small subset of rigorously proven SCC harbours EGFR mutation. It also appears in our cohort that EGFR-mutated tumours, in the context of SCC, may have relatively poor response to tyrosine kinase inhibitors.
(Copyright © 2020 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: